Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | PDCD1LG2 | Q9BQ51 | 4/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13771395 | 0.89 | MC4R (0.42) | MC4RKCNH2S1PR1PDCD1LG2CD274 | |
| SCHEMBL4071287 | 0.84 | KCNH2 (0.61) | MC4RKCNH2PDCD1LG2CD274NISCH | |
| SCHEMBL4071834 | 0.84 | MC4R (0.61) | MC4RKCNH2PDCD1LG2CD274NISCH | |
| SCHEMBL4073569 | 0.82 | MC4R (0.42) | MC4RKCNH2NISCHMAOAMAOB | |
| SCHEMBL4822799 | 0.81 | MC4R (0.75) | MC4RKCNH2 | |
| SCHEMBL13771523 | 0.78 | MC4R (0.49) | MC4RKCNH2S1PR1PDCD1LG2CD274 | |
| SCHEMBL4016721 | 0.75 | MC4R (0.67) | MC4RKCNH2 | |
| SCHEMBL13771403 | 0.75 | MC4R (0.54) | MC4RKCNH2PDCD1LG2CD274NISCH | |
| SCHEMBL13771398 | 0.73 | MC4R (0.52) | MC4RKCNH2PDCD1LG2CD274NISCH | |
| SCHEMBL4068780 | 0.72 | MC4R (0.51) | MC4RKCNH2PDCD1LG2CD274NISCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644337-B1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | ORE PHARMACEUTICALS INC (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| US-7375125-B2 | Melanocortin-4 receptor binding compounds and methods of use thereof | ORE PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1644337-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | Gene Logic, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005121100-A1 | MELANOCORTIN-4 RECEPTOR BINDING COMPOUNDS AND METHODS OF USE THEREOF | GENE LOGIC INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269217-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC3R | MC4R 1/4885KCNH2 3035/4885S1PR1 671/4885 |
| US-20040082779-A1 | Melanocortin-4 receptor binding compounds and methods of use thereof | MC4R, MC5R, MC1R | MC4R 1/4885KCNH2 3648/4885S1PR1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.